A new trading day began on Friday, with Tarsus Pharmaceuticals Inc (NASDAQ: TARS) stock price down -3.85% from the previous day of trading, before settling in for the closing price of $52.23. TARS’s price has ranged from $20.08 to $57.28 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -21.79% over the past five years. Meanwhile, its annual earnings per share averaged 30.35%. With a float of $32.58 million, this company’s outstanding shares have now reached $38.20 million.
Let’s look at the performance matrix of the company that is accounted for 244 employees. In terms of profitability, gross margin is 92.97%, operating margin of -108.47%, and the pretax margin is -103.64%.
Tarsus Pharmaceuticals Inc (TARS) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Tarsus Pharmaceuticals Inc is 14.76%, while institutional ownership is 97.13%. The most recent insider transaction that took place on Aug 12 ’24, was worth 912,961. In this transaction Director of this company sold 35,000 shares at a rate of $26.08, taking the stock ownership to the 0 shares. Before that another transaction happened on Aug 12 ’24, when Company’s Director proposed sale 35,000 for $26.85, making the entire transaction worth $939,750.
Tarsus Pharmaceuticals Inc (TARS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 30.35% per share during the next fiscal year.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Trading Performance Indicators
Here are Tarsus Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.81, a number that is poised to hit -0.74 in the next quarter and is forecasted to reach -1.54 in one year’s time.
Technical Analysis of Tarsus Pharmaceuticals Inc (TARS)
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) saw its 5-day average volume 0.45 million, a negative change from its year-to-date volume of 0.63 million. As of the previous 9 days, the stock’s Stochastic %D was 23.36%. Additionally, its Average True Range was 2.75.
During the past 100 days, Tarsus Pharmaceuticals Inc’s (TARS) raw stochastic average was set at 72.76%, which indicates a significant increase from 4.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.65% in the past 14 days, which was higher than the 46.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $51.93, while its 200-day Moving Average is $38.23. Nevertheless, the first resistance level for the watch stands at $51.82 in the near term. At $53.43, the stock is likely to face the second major resistance level. The third major resistance level sits at $54.33. If the price goes on to break the first support level at $49.31, it is likely to go to the next support level at $48.41. The third support level lies at $46.80 if the price breaches the second support level.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Key Stats
With a market capitalization of 1.92 billion, the company has a total of 38,227K Shares Outstanding. Currently, annual sales are 17,450 K while annual income is -135,890 K. The company’s previous quarter sales were 48,120 K while its latest quarter income was -23,420 K.
